Issue Archive

Research Summaries

FDA Approval

FDA Approval

FDA Approves Sacituzumab Govitecan (Trodelvy) for First-Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer

06/26/2026

Anthony Calabro, MA

The FDA approved sacituzumab govitecan-hziy (Trodelvy) as monotherapy, and with pembrolizumab-based therapy, for select adults with previously untreated unresectable locally advanced or metastatic...

06/26/2026

Conference Coverage

Brett Snodgrass, DNP, FNP-C, and Steven Stanos, DO

Conference Coverage

Case-Based Evaluation and Multimodal Management of Acute, Chronic Low Back Pain in Primary Care

06/26/2026

Anthony Calabro, MA

Using real-world patient scenarios and current guideline recommendations, this session from Practical Updates in Primary Care outlines a structured primary care approach to diagnosing low back pain,...

06/26/2026

FDA Approval

FDA Approval

FDA Approves Belzutifan (Welireg) Plus Pembrolizumab (Keytruda) for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma

06/25/2026

Anthony Calabro, MA

The FDA approved expanded adjuvant therapy options for adults with renal cell carcinoma with a clear cell component who are at intermediate-high or high risk of recurrence after nephrectomy, with or without...

06/25/2026

Disease State Pillar

Disease State Pillar

06/25/2026

Anthony Calabro, MA

IgG4-related disease is unlikely to be the first diagnosis suspected in primary care, but PCPs may be the first clinicians to recognize the atypical, recurrent, mass-like, or multiorgan patterns that should...

06/25/2026

Research Summary

Research Summary

Cefazolin Noninferior to Flucloxacillin/Cloxacillin for 90-Day Mortality in Adult MSSA Bacteremia

06/25/2026

Anthony Calabro, MA

In an international Bayesian adaptive RCT of adults with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin for 90-day all-cause mortality and was associated with less acute kidney...

06/25/2026

June 2026

Current Issue

June 2026

Issue Archive

2007

2006

2005

2004

2003

2002

Research Summaries

June 2026